리포솜 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2031년) - 제품별, 용도별, 유통 채널별, 지역별
Liposomes Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
상품코드:1485949
리서치사:Fairfield Market Research
발행일:2024년 05월
페이지 정보:영문 201 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계 리포솜 시장 규모는 2024년 74억 달러에서 2031년 106억 7,000만 달러로 연평균 5.2%의 성장률을 기록할 것으로 예상됩니다. 약물전달 시스템의 발전과 만성 질환의 증가에 의해 주도되고 있습니다.
리포솜 약물전달 시스템의 혁신은 제약 산업에 혁명을 일으키고 있습니다. 리포솜은 작은 크기, 생체 적합성, 화학적 안정성으로 인해 나노 의료에 필수적인 것으로 알려져 있습니다. 리포솜은 유효 성분의 효능을 향상시키는 능력으로 인해 약물전달에 리포솜이 선택되고 있으며, 이는 유효 기간 연장, 제형 개선 등 다양한 이점이 있습니다.
리포좀 제제는 피부과 및 기타 의료 분야에서 국소 치료제로 개발되어 리포좀 기반 기술의 중요성을 강조하고 있습니다. 기술의 발전과 함께 리포좀 나노기술은 특히 공중 보건 및 의료 진단 분야에서 더욱 신뢰할 수 있는 제조 플랫폼이 될 것으로 예상됩니다.
이 보고서는 세계 리포솜 시장에 대해 조사했으며, 시장 개요와 함께 제품별, 용도별, 유통 채널별, 지역별 동향, 시장 진입 기업의 경쟁 동향 등을 조사하여 전해드립니다.
목차
제1장 주요 요약
제2장 시장 개요
시장 정의와 세분화
시장 역학
밸류체인 분석
Porter's Five Forces 분석
COVID-19의 영향 분석
우크라이나·러시아 분쟁의 영향
경제 개요
PESTLE 분석
제3장 세계의 리포솜 시장 전망, 2018-2031년
세계의 리포솜 시장 전망, 제품별, 금액(10억 달러), 2018-2031년
세계의 리포솜 시장 전망, 용도별, 금액(10억 달러), 2018-2031년
세계의 리포솜 시장 전망, 유통 채널별, 금액(10억 달러), 2018-2031년
세계의 리포솜 시장 전망, 지역별, 금액(10억 달러), 2018-2031년
제4장 북미의 리포솜 시장 전망, 2018-2031년
제5장 유럽의 리포솜 시장 전망, 2018-2031년
제6장 아시아태평양의 리포솜 시장 전망, 2018-2031년
제7장 라틴아메리카의 리포솜 시장 전망, 2018-2031년
제8장 중동 및 아프리카의 리포솜 시장 전망, 2018-2031년
제9장 경쟁 상황
제품별과 용도별 히트맵
기업 시장 점유율 분석, 2023년
경쟁 대시보드
기업 개요
Novartis AG(Liposoma BV)
Precision NanoSystems Inc
Janssen Pharmaceutical Companies
Encapsula Nano Sciences
Synpac-Kingdom Pharmaceutical Co., Ltd
Celsion GmbH
Gilead Sciences, Inc
Pacira BioSciences, Inc.
Luye Pharma Group
Sun Pharma Industries Ltd
제10장 부록
ksm
영문 목차
영문목차
The global liposomes market is projected to experience significant expansion, with valuations anticipated to rise from $7.4 billion in 2024 to an impressive $10.67 billion by 2031. This represents a consistent CAGR of 5.2%, driven by advancements in drug delivery systems and the rising prevalence of chronic diseases.
Technological Breakthroughs in Liposomal Drug Delivery Systems
Innovations in liposomal drug delivery systems are revolutionizing the pharmaceutical industry. Known for their small size, biocompatibility, and chemical stability, liposomes have become integral in nanomedicine. Their ability to enhance the effectiveness of active pharmaceutical ingredients-such as prolonging shelf life and improving drug formulations-has made them a preferred choice for drug delivery.
The development of liposomal formulations for topical treatments in dermatology and other medical applications highlights the growing importance of liposome-based technologies. As technology advances, liposomal nanotechnology is expected to become a more dependable manufacturing platform, especially in public health and medical diagnostics.
Rising Demand for Liposomal Drugs
The demand for liposomal drugs is increasing due to the higher prevalence of chronic diseases, cancer, and lifestyle-related disorders such as diabetes and obesity. Liposomal drugs provide a promising solution for treating severe diseases because of their targeted delivery mechanisms and minimized side effects.
In emerging markets such as India, Mexico, and Brazil, the expanding patient population and greater awareness of health and wellness present substantial market opportunities. The increasing disposable income and economic growth in these regions further support the long-term viability of the liposomes market.
Enhancing Healthcare Infrastructure
The improvement of healthcare infrastructure and increased healthcare spending by governments in both developed and developing nations are key drivers of market growth. Better healthcare infrastructure enhances access to advanced therapeutics, thereby increasing the demand for liposomal drugs.
In countries like the United States, the high prevalence of chronic diseases, a strong healthcare infrastructure, and the presence of leading market players are contributing to market growth. For example, the American Cancer Society's 2022 report noted over 1.9 million new cancer cases and more than 609,360 cancer-related deaths, highlighting the need for advanced therapeutics.
Promising Market in Germany
Germany's extensive research and development activities in lipid pharmaceuticals, particularly for cardiovascular diseases (CVDs), are expected to further drive the liposomes market. With cardiovascular disorders being the leading cause of death in Germany-accounting for over 40% of all fatalities-the development of novel liposomal medications is crucial for reducing the prevalence and healthcare costs associated with CVDs.
Emerging Market in China
China is emerging as a key market for liposomes, driven by the increasing prevalence of chronic diseases, a growing elderly population, and market penetration by international players. The country's large patient pool and demand for new medications, such as liposomal drugs, present significant growth opportunities.
Key Distribution Channels
Pharmacies are the primary distribution channel for liposomal drugs, holding around 90.2% of the total market share in 2022. The high prevalence of chronic and skin diseases fuels the demand for liposomal drugs for therapeutic purposes. According to WHO estimates, non-communicable diseases (NCDs) cause 41 million deaths annually, with cardiovascular diseases and cancers being the leading causes.
Competitive Landscape
Leading players in the liposomes market are employing various strategies, including collaborations and the launch of new products. Notable developments include:
In January 2022, Pfizer Inc. and Acuitas Therapeutics signed a development and opportunity agreement, allowing Pfizer to develop vaccines using Acuitas' lipid nanoparticle (LNP) technology.
In October 2021, Evonik introduced a new version of LIPEX(R) liposome extruders. LIPEX(R) Flow offers a superior solution for drug designers and manufacturers, aiding the market introduction of liposomal pharmaceuticals.
The global liposomes market is set to witness considerable growth in the coming years, driven by technological advancements, increasing demand for advanced therapeutics, and strategic collaborations among key players.
